Cite
Vassilev L, Ranki T, Joensuu T, et al. Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8. Oncoimmunology. 2015;4(7):e1017702doi: 10.1080/2162402X.2015.1017702.
Vassilev, L., Ranki, T., Joensuu, T., Jäger, E., Karbach, J., Wahle, C., Partanen, K., Kairemo, K., Alanko, T., Turkki, R., Linder, N., Lundin, J., Ristimäki, A., Kankainen, M., Hemminki, A., Backman, C., Dienel, K., von Euler, M., Haavisto, E., Hakonen, T., Juhila, J., Jäderberg, M., Priha, P., Vuolanto, A., & Pesonen, S. (2015). Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8. Oncoimmunology, 4(7), e1017702. https://doi.org/10.1080/2162402X.2015.1017702
Vassilev, L, et al. "Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8." Oncoimmunology vol. 4,7 (2015): e1017702. doi: https://doi.org/10.1080/2162402X.2015.1017702
Vassilev L, Ranki T, Joensuu T, Jäger E, Karbach J, Wahle C, Partanen K, Kairemo K, Alanko T, Turkki R, Linder N, Lundin J, Ristimäki A, Kankainen M, Hemminki A, Backman C, Dienel K, von Euler M, Haavisto E, Hakonen T, Juhila J, Jäderberg M, Priha P, Vuolanto A, Pesonen S. Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8. Oncoimmunology. 2015 Apr 01;4(7):e1017702. doi: 10.1080/2162402X.2015.1017702. eCollection 2015 Jul. PMID: 26140248; PMCID: PMC4485730.
Copy
Download .nbib